S&P 500 Industrials Sector SEC Filings — April 06, 2026

06-04-2026

On April 6, 2026, NioCorp Developments Ltd. held its Annual Meeting where shareholders approved the Amended and Restated Shareholder Rights Plan, extending its term to the 2027 annual meeting, and the 2017 Amended Long-Term Incentive Plan, authorizing up to 11,300,000 Common Shares for options, RSUs, and other awards, replacing the prior evergreen share limit. Shareholders also set the board at six directors, elected nominees (with significant withheld votes for some, e.g., 8.4M for Nilsa Guerrero-Mahon), appointed Deloitte & Touche LLP as auditors, and approved advisory say-on-pay, though several proposals saw notable opposition (e.g., 5.3M against LTIP amendment) amid 125,321,172 shares outstanding and only 56,773,600 present.

• ·Proposal One (Set directors at six): 55,164,407 For; 1,609,193 Against.
• ·Proposal Three (Appoint auditors): 55,986,839 For; 786,761 Withheld.
• ·Proposal Four (Say-on-pay advisory): 22,285,849 For; 6,272,537 Against; 397,390 Abstentions; 27,817,824 broker non-votes.
• ·Proposal Five (LTIP amendment): 23,285,354 For; 5,326,885 Against; 343,535 Abstentions; 27,817,826 broker non-votes.
• ·Proposal Six (Rights Plan amendment): 23,942,251 For; 4,719,596 Against; 293,931 Abstentions; 27,817,822 broker non-votes.
• ·Director elections broker non-votes ~27.8M each; withheld votes ranged 993,498 (Fulton) to 8,398,816 (Guerrero-Mahon).

06-04-2026

Genworth Financial, Inc. (GNW) has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on May 20, 2026, at 9:00 a.m. ET virtually. Shareholders are to vote on electing ten director nominees, advisory approval of named executive officer compensation, approval of the 2026 Associate Stock Purchase Plan, and ratification of KPMG LLP as the independent auditor for 2026, with the Board recommending 'FOR' all items. No financial performance metrics or period comparisons are provided in the filing.

• ·Vote deadline: May 19, 2026 11:59 PM ET (May 17 for Plan shares, May 18 for Canadian Plan shares)
• ·Request proxy materials by May 6, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/GNW2026
• ·This is the Board's WHITE proxy card

06-04-2026

Baker Hughes Company filed a supplement to its March 30, 2026 Proxy Statement on April 6, 2026, specifically revising the voting standards description on page 88 for the 2026 Annual Meeting of Shareholders on May 19, 2026. The update details quorum requirements (majority of Common Stock present or by proxy) and majority-of-votes-cast standards for director elections, advisory vote on executive compensation, ratification of KPMG LLP as auditor for fiscal year 2026, approval of the 2026 Long-Term Incentive Plan, and the Second Amended and Restated Employee Stock Purchase Plan. The supplement does not alter any proposals, board recommendations, or require action from shareholders who have already voted unless they choose to change their vote.

• ·Abstentions and broker non-votes have no effect on director elections or the specified proposal approvals.
• ·Capitalized terms in the supplement refer to definitions in the original Proxy Statement.

06-04-2026

Oxbridge Re Holdings Limited filed a 10-K/A amendment on April 6, 2026, disclosing grants of restricted shares to NEOs Mr. Madhu and Mr. Timothy in fiscal year 2025 under the 2021 Omnibus Incentive Plan, subject to vesting over three quarters based on continued employment. Equity compensation plans approved by shareholders show 451,250 securities to be issued upon exercise at a weighted average price of $5.42, with 1,569,514 securities remaining available for future issuance. The filing includes an extensive list of exhibits referencing various incentive plans, employment agreements, and other corporate documents, many incorporated by reference from prior 8-K filings.

• ·Restricted shares granted to NEOs carry shareholder rights including dividends and were valued using FASB ASC Topic 718 grant date fair value.
• ·Exhibits include amended employment agreements dated August 28, 2025 for Jay Madhu and Wrendom Timothy, and corporate action agreements for Sanjay Madhu and Wrendom Timothy.
• ·Equity Distribution Agreement dated July 9, 2025 with Maxim Group LLC.

06-04-2026

The Honest Company, Inc. entered into the First Amendment to its Credit Agreement and Pledge and Security Agreement, both originally dated January 25, 2023, as of March 31, 2026, subject to conditions precedent including executed documents, legal opinions, secretary certificates, and representations of no Default or Event of Default. The amendments update specific sections, schedules, exhibits, and render Section 2 of the Fee Letter inapplicable, while ratifying the existing loan documents without waiving any rights or remedies. No quantitative changes to facility terms are disclosed in the filing.

• ·Amendment filed as 8-K on April 06, 2026 (Items 1.01, 1.02, 2.03, 9.01).
• ·Governed by laws of the State of California.
• ·Executed in counterparts with electronic signatures permitted.

06-04-2026

Biogen Inc. expects approximately $34 million in acquired in-process research and development, upfront and milestone expenses for the first quarter of 2026 on a pre-tax basis, negatively impacting both GAAP and non-GAAP net income per diluted share by about $0.19. These preliminary unaudited results for the quarter ended March 31, 2026, are subject to final financial statement closing procedures and may differ from final figures. The company notes uncertainty in forecasting such expenses due to their unpredictable timing and magnitude.

• ·Expenses include costs from collaboration and license agreements, such as upfront and milestone payments, premiums on equity securities, and asset acquisitions.
• ·Biogen does not forecast such acquired in-process research and development expenses due to uncertainty in future occurrence, magnitude, and timing.

06-04-2026

Legence Corp. filed an S-1 registration statement on April 6, 2026, presenting unaudited pro forma condensed combined financial information reflecting its acquisition of The Bowers Group, Inc. (Bowers) completed on January 2, 2026, for total estimated consideration of $426.6 million, including $283.1 million cash, 2,551,672 shares of Class A common stock valued at $98.6 million, and $44.9 million deferred consideration. Pro forma combined revenue for the year ended December 31, 2025, reaches $3,449,898 thousand, combining Legence's historical $2,550,491 thousand with Bowers' $902,357 thousand after adjustments, while pro forma total assets stand at $3,265,176 thousand as of December 31, 2025. The acquisition was financed via a $200.0 million incremental term loan, cash on hand, and revolver borrowings, following Legence's prior IPO in September 2025 which raised net proceeds of $780.2 million.

• ·Pro forma combined total liabilities as of December 31, 2025: $2,390,907 thousand.
• ·Pro forma combined total equity as of December 31, 2025: $874,269 thousand.
• ·IPO commenced trading on Nasdaq Global Select Market on September 12, 2025, and closed on September 15, 2025.
• ·Acquisition shares subject to lock-up through March 10, 2026.

06-04-2026

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced a proposed underwritten public offering of shares of its common stock and accompanying Series A and Series B warrants (or pre-funded warrants in lieu thereof), all to be sold by the company. Piper Sandler is acting as sole manager, with INOVIO intending to grant a 30-day underwriter option to purchase up to 15% additional securities under the same terms. The offering is subject to market conditions, with no assurance of completion, size, or terms, and will be made via a prospectus supplement to a previously effective shelf registration.

• ·Shelf registration statement filed with SEC on November 9, 2023, and declared effective on January 31, 2024.
• ·Prospectus available via Piper Sandler at (800) 747-3924 or prospectus@psc.com.
• ·INOVIO focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases.

06-04-2026

On March 31, 2026, Carlson Thow resigned as Chief Executive Officer of Treasure Global Inc., effective immediately, but will remain a member of the Board of Directors. Chong Chan Teo was promoted to Acting Chief Executive Officer effective April 1, 2026, with an adjusted monthly salary of RM 22,000. No other financial impacts or performance metrics were disclosed.

• ·Chong Chan Teo previously served as CEO from July 2020 to June 2024 and currently as Executive Director and Head of Operations.
• ·Teo's prior roles include Director of Business Development at ZCITY and Managing Director of Modes Cube Sdn Bhd.
• ·Company is an emerging growth company listed on Nasdaq under TGL.

06-04-2026

Verizon Communications Inc. filed its DEF 14A Proxy Statement on April 6, 2026, ahead of the annual shareholder meeting on May 21, 2026. The document includes Pay vs. Performance disclosures detailing reported compensation, equity award adjustments, pension benefit changes, and other components for Principal Executive Officers (Vestberg through October 3, 2025, and Schulman from October 4, 2025) and non-PEO Named Executive Officers across fiscal years 2021-2025. No specific performance metrics or financial results are quantified in the provided filing content.

• ·Company address: 1095 Avenue of the Americas, New York, NY 10036
• ·Fiscal year end: December 31
• ·Business phone: 212-395-1000
• ·State of incorporation: Delaware
• ·Former name: Bell Atlantic Corp (changed July 3, 1992)

06-04-2026

Inogen, Inc. (Nasdaq: INGN) announced the appointment of Vafa Jamali, a seasoned medical device executive with prior leadership at ZimVie, Covidien, and Medtronic (including a $3 billion division), as an independent director to its Board, effective at the 2026 Annual Meeting or June 15, 2026, whichever is earlier. The appointment is accompanied by a cooperation agreement with Kent Lake Partners LP, Kent Lake PR LLC, and Benjamin Natter, including standstill and voting provisions. Company leadership expressed optimism about Jamali's contributions to Inogen's transformation into a diversified respiratory care platform and ongoing growth initiatives.

• ·Cooperation agreement includes customary standstill, voting, and other provisions; to be filed as exhibit to Form 8-K
• ·Advisors: Evercore (financial), Covington & Burling LLP (legal), Joele Frank, Wilkinson Brimmer Katcher (strategic communications)

06-04-2026

Bank of the James Financial Group, Inc. (BOTJ) issued Definitive Additional Proxy Materials (DEFA14A) for its 2026 Annual Meeting on May 19, 2026, at 1:00 p.m. ET virtually. Key voting items include the election of four director nominees (Robert R. Chapman III, Julie P. Doyle, Lydia K. Langley, Augustus A. Petticolas, Jr.), ratification of Elliott Davis, PLLC as independent auditors for the fiscal year ending December 31, 2026, and an advisory vote on executive compensation. No other business is anticipated beyond procedural matters.

• ·Vote deadline: May 18, 2026, 11:59 PM ET at www.proxyvote.com
• ·Material request deadline: May 5, 2026 via www.proxyvote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Virtual meeting access: www.virtualshareholdermeeting.com/BOTJ2026
• ·Filing date: April 6, 2026

06-04-2026

Enphase Energy sold $235,000,000 in advanced manufacturing production tax credits (generated in 2025) to a leading financial institution for $218,550,000 in cash on March 31, 2026, at 93% of face value. The transaction incurred a $16.5 million discount and $2.5 million in fees, which will reduce GAAP gross margin for Q1 2026 by 6.7 percentage points versus prior guidance, though excluded from non-GAAP measures. This provides significant cash inflow but negatively impacts reported GAAP profitability.

• ·Tax credits generated from production and sale of eligible components in the United States during calendar year 2025.
• ·Agreement includes customary covenants, indemnification, and termination provisions.
• ·Filing date: April 6, 2026; Effective Date: March 31, 2026.

06-04-2026

Lise J. Buyer resigned from The Trade Desk, Inc.'s board of directors, effective April 3, 2026, after informing the company on March 31, 2026. Her resignation was not due to any disagreement with the company's operations, policies, or practices. She had served on the board since March 2019, and the board expressed thanks for her service.

• ·Filing date: April 6, 2026

06-04-2026

Howmet Aerospace Inc. filed DEFA14A additional proxy materials for its 2026 Annual Shareholders Meeting scheduled virtually on May 19, 2026, at 9:00 A.M. ET. Key voting items include the election of nine director nominees, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, and an advisory vote to approve executive compensation. Proxy materials are available at www.ProxyVote.com, with voting deadline May 18, 2026, 11:59 P.M. ET.

• ·Meeting location: www.virtualshareholdermeeting.com/HWM2026
• ·Material request deadline: May 5, 2026
• ·Address: C/O Corporate Secretary’s Office, 201 Isabella Street Suite 200, Pittsburgh, PA 15212

06-04-2026

Dr. Christopher Lin, Ph.D., a member of RBB Bancorp's Board of Directors and Royal Business Bank's Board of Directors, advised on April 1, 2026, that he will retire effective as of the Company's 2026 Annual Meeting of Shareholders and will not stand for re-election. He currently serves on the Audit Committee, Directors Loan Committee, and Community Reinvestment Act Committee, from which he will also retire. His decision did not involve any disagreement with Company management, the Board, or the Bank Board on operations, policies, or practices.

• ·Date of earliest event reported: April 1, 2026
• ·Filing signed by Lynn Hopkins on April 6, 2026

06-04-2026

Public Storage Operating Company (PSOC), a subsidiary of Public Storage, completed a $500 million offering of 5.000% Senior Notes due 2035 on April 6, 2026, guaranteed by Public Storage. The Notes bear interest at 5.000% per annum, payable semi-annually commencing June 15, 2026, and mature on December 15, 2035, with redemption options at a make-whole price or 100% of principal after September 15, 2035. The issuance is under an existing Indenture with covenants limiting indebtedness and requiring at least 125% unencumbered assets to unsecured debt.

• ·Notes are unsecured and unsubordinated, ranking equally with PSOC's existing and future similar indebtedness.
• ·Interest accrues from April 6, 2026; semi-annual payments on June 15 and December 15.
• ·Indenture includes customary events of default and limitations on mergers, consolidations, or asset sales.

06-04-2026

Citius Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders on April 6, 2026, electing seven directors—Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis M. McGrath, Robert Smith, and Carol Webb—for one-year terms, with For votes ranging from 2,311,462 to 2,485,904, Withheld votes from 976,783 to 1,151,225, and 6,660,992 broker non-votes across all nominees. Stockholders ratified Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with 8,593,946 votes for, 855,866 against, and 673,867 abstentions.

• ·All seven director nominees received between 2,311,462 and 2,485,904 For votes and 976,783 to 1,151,225 Withheld votes.
• ·No broker non-votes on auditor ratification.

06-04-2026

AvalonBay Communities, Inc. has filed its 2026 Proxy Statement for the virtual Annual Meeting on May 20, 2026, seeking stockholder approval for the election of 12 directors, a non-binding advisory vote on named executive officer compensation, adoption of the 2026 Equity Incentive Plan to replace the expiring plan, and ratification of Ernst & Young LLP as independent auditors for 2026. The record date is March 23, 2026. No financial performance metrics or period-over-period comparisons are detailed in the filing excerpt.

• ·Annual Meeting: May 20, 2026, 10:00 a.m. Eastern Time, virtual via www.virtualshareholdermeeting.com/AVB2026
• ·Record date: March 23, 2026
• ·Proxy materials available on or about April 6, 2026 at www.proxyvote.com
• ·References compensation data for Benjamin W. Schall (2023-2025) and Timothy J. Naughton (2021-2022) via XBRL tags, but no numerical values provided in excerpt

06-04-2026

Phillips 66 provided preliminary Q1 2026 guidance showing pre-tax mark-to-market losses of approximately $900 million due to sharp commodity price increases, with a net short derivative position of 50 million barrels, impacting Refining ($350-450M loss), Marketing and Specialties ($300-400M loss), and Renewable Fuels ($100-200M loss). While Midstream income before taxes is estimated at $550-600M and Chemicals at $80-130M, Refining ($400-200M loss), Marketing and Specialties ($170-20M loss), Renewable Fuels ($150-50M loss), and Corporate ($470-450M loss) show significant losses; additional headwinds include $300M refining pricing lag, midstream downtime from Winter Storm Fern, and lower Chemicals utilization. Commodity volatility led to $3B cash collateral outflow, prompting liquidity actions like a $2.25B term loan draw, maintaining $6B liquidity amid $27B total debt and $22B net debt.

• ·Chemicals special item adjustment of ($30)M.
• ·Marketing and Specialties special item adjustment of $20M.
• ·Debt target of $17B by end of 2027.

06-04-2026

This DEFA14A filing contains proxy solicitation scripts and materials for a special shareholder meeting of the Fidelity Advisor Health Care Fund on May 12, 2026, proposing a merger into the Fidelity Select Health Care Portfolio. The Board of Trustees and portfolio manager Eddie Yoon strongly recommend voting FOR the proposal, highlighting benefits such as increased management flexibility to take larger positions in high-conviction stocks for potential better performance. No financial metrics or performance data are provided in the materials.

• ·Requires simple majority shareholder approval to proceed
• ·Dedicated toll-free voting number: 888-381-8296 (available Monday-Friday, 9AM-10PM ET)
• ·Proxy materials available via 1-877-208-0098 or www.sec.gov

06-04-2026

Rocket Pharmaceuticals, Inc. filed a DEFA14A Definitive Additional Materials proxy statement on April 06, 2026. The filing is by the registrant with no fee required and contains standard header information without substantive business or financial disclosures.

06-04-2026

Steven Madden, Ltd. (SHOO) filed a DEFA14A (Schedule 14A) definitive additional proxy materials on April 06, 2026. The filing is made by the registrant with no fee required. No substantive proxy details, financial data, or voting matters are included in the provided filing header.

06-04-2026

NeoGenomics, Inc. (NEO) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on April 06, 2026. The filing indicates no fee was required and is part of the proxy solicitation process under Section 14(a) of the Securities Exchange Act of 1934. No specific proposals, financial data, or voting matters are detailed in the provided filing header.

06-04-2026

Horace Mann Educators Corporation filed a DEFA14A definitive additional proxy materials on April 06, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive financial or operational details are provided in the document header.

06-04-2026

Immix Biopharma, Inc. (IMMX) filed a DEFA14A Definitive Additional Materials proxy statement on April 6, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is not preliminary, confidential, or soliciting material under specific rules. No substantive proposals, financial data, or other details are provided in the filing header.

06-04-2026

On April 3, 2026, Murphy USA Inc. appointed Donald R. Smith, Jr., its current Interim Chief Financial Officer, Vice President, Chief Accounting Officer & Treasurer, as permanent Senior Vice President, Chief Financial Officer and Treasurer. The appointment includes an increased annual base salary of $550,000, target annual cash bonus of 70% of base salary, target long-term equity incentive of 125% of base salary, a one-time cash bonus of $45,000, and a 2026 equity top-up award valued at $260,000 (50% performance stock units, 25% restricted stock units, 25% stock options). There are no family relationships or material conflicts of interest.

• ·Mr. Smith employed by Murphy USA since 2013 spin-off, initially as Vice President and Controller (Chief Accounting Officer).
• ·Named Treasurer in 2024 and Interim CFO in October 2025.
• ·No family relationships between Mr. Smith and any officer or director.
• ·Mr. Smith has no direct or indirect material interest in transactions under Item 404(a) of Regulation S-K.

06-04-2026

Banner Corporation (BANR) filed a DEFA14A definitive additional proxy materials on April 06, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials for shareholder solicitation. No financial data, performance metrics, or specific agenda items are disclosed in this cover filing.

• ·Filing marked as 'Filed by the registrant' with no other party indicated.
• ·Soliciting material pursuant to § 240.14a-12.

06-04-2026

Southern First Bancshares, Inc. (SFST) filed its DEF 14A proxy statement on April 6, 2026, for the annual shareholder meeting on May 19, 2026, with a record date of March 20, 2026, and 8,247,710 shares of common stock outstanding. Shareholders will vote on director elections by plurality, an advisory approval of named executive officer compensation, and ratification of Elliott Davis, LLC as independent auditors for the year ending December 31, 2026. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Record date: March 20, 2026
• ·Annual meeting date: May 19, 2026
• ·Quorum requirement: majority of outstanding shares
• ·Voting on director election by plurality; advisory votes on compensation and auditor ratification
• ·Company address: 6 Verdae Boulevard, Greenville, SC 29607

06-04-2026

Stoneridge, Inc. filed an 8-K/A on April 6, 2026, amending its February 23, 2026 Form 8-K to provide compensation details for Natalia Noblet, appointed President and Chief Executive Officer effective April 1, 2026. Her annual base salary is €490,475 (approximately $568,568 USD at €1.00 = $1.16 exchange rate), with a 2026 annual incentive target of 100% of base salary and long-term incentive target of 125% of base salary. The Compensation Committee delegated authority to the Chairperson to approve her employment agreement, with material terms to be disclosed in a future filing.

• ·Appointment announced February 19, 2026, effective 12:01 a.m. April 1, 2026
• ·Compensation Committee to approve employment agreement covering term, duties, termination, severance, change-in-control protections, and restrictive covenants; material terms to be filed within four business days of execution

06-04-2026

Integer Holdings Corporation (ITGR) filed a DEFA14A Definitive Additional Proxy Materials on April 06, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific proxy proposals, financial data, or other substantive content is detailed in the provided filing header.

• ·Filing Type: DEFA14A (Proxy Statement Amendment)
• ·Checked as Definitive Additional Materials

06-04-2026

Alnylam Pharmaceuticals, Inc. filed a DEFA14A Definitive Additional Proxy Materials on April 06, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing is marked as soliciting material under §240.14a-12 with no fee required. No specific financial metrics, performance data, or shareholder proposals are detailed in the provided filing header.

• ·Filing classified as Definitive Additional Materials (not Preliminary or Definitive Proxy Statement).

06-04-2026

Geospace Technologies Corporation implemented an organizational change plan at the end of Q2 FY2026, including a Voluntary Early Retirement plan and Reduction in Force, resulting in approximately 20% reduction in global workforce and expected $10 million annualized cash savings. However, the company anticipates incurring $0.6 million in termination costs in Q2 FY2026 and $0.7 million in Q3 FY2026 ending June 30, 2026, primarily for employee transition, severance, and benefits.

• ·Event reported date: April 2, 2026; Filing date: April 6, 2026

06-04-2026

DeFi Development Corp. (Nasdaq: DFDV) appointed Adam Townsend, former Vice President and CFO of VIZIO at Walmart Inc., to its Board of Directors on April 6, 2026. Townsend oversaw the financial integration of VIZIO's $2.3 billion acquisition by Walmart, led VIZIO through its 2021 IPO and 2024 sale, and brings extensive experience from Showtime Networks, CBS Corporation, E*TRADE, and JPMorgan. CEO Joseph Onorati praised Townsend's capital markets and treasury expertise to aid scaling, capital raising, and institutional investor engagement for the company's Solana treasury strategy.

• ·VIZIO IPO completed in 2021
• ·VIZIO sold to Walmart in 2024
• ·Company provides direct exposure to SOL via treasury holdings, staking rewards, and DeFi participation

06-04-2026

Deep Isolation Nuclear, Inc., formerly Aspen-1 Acquisition Inc., filed Amendment No. 4 to its Form S-1 registration statement on April 6, 2026, registering 58,506,213 shares of common stock for resale by selling stockholders, including shares from a July 23, 2025 merger with Deep Isolation, Inc., a concurrent private placement of 11,012,387 shares, and other issuances. The company expects no proceeds from these resales but may receive up to $2,489,206.67 from cash exercises of 996,397 placement agent warrants. There is currently no public trading market, with shares initially offered at a fixed $3.00 per share totaling $175,518,639 until quoted on OTCQB or similar.

• ·Merger and Private Placement closed on July 23, 2025.
• ·Company name changed from Aspen-1 Acquisition Inc. on March 17, 2022.
• ·Shares not currently eligible for trading on Nasdaq, OTCQB, or any exchange; intent to apply for OTCQB quotation post-effectiveness.
• ·Emerging growth company and smaller reporting company status.

06-04-2026

Shepherd's Finance, LLC's 2025 net income declined 19% YoY to $1,413 thousand from $1,737 thousand, driven by a 25% rise in SG&A expenses to $3,824 thousand and higher provisions for credit losses at $1,066 thousand, despite net interest and fee income increasing 7% to $5,732 thousand. Net income attributable to common equity holders plunged 59% to $425 thousand from $1,035 thousand, while non-interest income fell 6% to $3,644 thousand amid lower revenue from land sales and option fees. Weighted average outstanding loan balances decreased 5% to $52,941 thousand, with total unpaid balances at $61,683 thousand showing 94.9% current but 5.1% past due.

• ·Total non-interest expense increased to $6,897 thousand in 2025 from $6,734 thousand in 2024.
• ·Delinquency breakdown: 2.3% 60-89 days past due ($1,439 thousand), 1.8% 90-179 days ($1,157 thousand), 0.7% 180-269 days ($446 thousand), 0.3% >270 days ($134 thousand).

06-04-2026

Abra Financial Holdings, Inc., party to a Business Combination Agreement dated March 16, 2026 with New Providence Acquisition Corp. III, announced that its CEO Bill Barhydt participated in an interview on the Wolf of All Streets podcast on April 5, 2026, expressing strong bullishness on decentralized financial infrastructure, tokenization, and increased interest from traditional finance firms following the going-public announcement about 20 days prior. Barhydt highlighted Abra's resilience through past crypto cycles and noted proactive outreach from TradFi for DeFi and custody solutions, with no price discussions beyond Bitcoin borrowing. While optimistic on Bitcoin's long-term potential despite possible short-term capitulation to the mid-50Ks (around 7% drop), he emphasized the sector's 'pre-disastered' state attracting institutions.

• ·Business Combination Agreement dated March 16, 2026
• ·Interview date: April 5, 2026
• ·Filing date: April 6, 2026
• ·Going-public announcement approximately 20 days before interview

06-04-2026

Cantor Fitzgerald Income Trust, Inc. filed an 8-K on April 6, 2026, under Item 7.01 for Regulation FD Disclosure. No specific core event, financial metrics, transactions, or quantitative details are provided in the filing summary. This appears to be a single-item, voluntary disclosure.

06-04-2026

For the nine months ended September 30, 2025, Nutra Pharma Corp reported total net sales of $331,241, up 22.4% YoY from $270,620, driven by a 39.1% increase in non-related party sales to $228,748, with gross profit rising 29.7% to $208,535. However, operating expenses surged 40.0% to $1,204,959, resulting in a widened net loss of $1,558,866 (47.8% worse YoY), cash burned $944,146 in operations (vs. $245,749 prior), and ending cash fell 90.1% to $3,603. Total assets grew 18.4% to $709,853, but liabilities increased 10.8% to $17,060,633 and stockholders' deficit deepened 10.4% to $16,350,780.

• ·Net cash used in operating activities for nine months ended Sep 30, 2025: $944,146 (vs. $245,749 in 2024)
• ·Cash flows from financing activities provided $962,354 for nine months ended Sep 30, 2025
• ·Investment in Stemsation stocks: $17,600 (unchanged)
• ·Receivable from sale of Stemsation stocks: $52,800 (unchanged)